NEWS
MAKING CHANGE HAPPEN JDRF & ARECOR
AGREEMENT
Nemaura Medical and Changing Health
have announced a partnership to provide
award-winning diabetes behavioural
change services. The companies will
join forces to provide innovative digital
education and personalized coaching
to enhance outcomes for people with
diabetes and prediabetes.
Nemaura Medical is a medical
technology company set to launch a
new CGM product, sugarBEAT. This is a
non-invasive continuous glucose monitor
(CGM), together with BEATdiabetes, a
health subscription service designed to
help people with diabetes and prediabetes
by offering lifestyle coaching.
The partnership with Changing Health
will bring digital behaviour programs
to improve the management, reversal
and prevention of Type 2 diabetes
commencing with the UK and Ireland.
Changing Health is a provider of digital
coaching services to the NHS England
aimed at the prevention or reversal of Type
2 diabetes.
The partnership will use CGM data
and daily glucose trend data provided by
Arecor Ltd has signed a Research,
Development and Commercialisation
agreement with JDRF, the leading global
organisation funding Type 1 diabetes (T1D)
research.Under this collaboration, Arecor
and JDRF will contribute matching funds
to develop a stable, liquid co-formulation
of pramlintide and insulin (AT271).
It has been demonstrated that the
combined injection of pramlintide and
insulin at meal-times results in significantly
improved treatment outcomes, such as
enhanced post prandial glucose control,
improved HbA1c, weight loss and
concomitant reduction in insulin doses.
Currently pramlintide is underutilised
despite these significant benefits as it
requires the patient to administer daily
injections in addition to their insulin
injections. Therefore, combination
treatment, AT271, should reduce the
burden of use by providing a single
injection treatment option for pramlintide
and prandial insulin.
Arecor will use its proprietary
formulation technology platform, Arestat,
to develop a new, co-formulation of
pramlintide and insulin, which will include
non-clinical studies to develop a new
product. This contract will be managed
under the JDRF standard terms for
industry partnerships.
JDRF scientist Jonathan Rosen, PhD,
said: "Arecor's expertise in enhancing
current therapies supports our drive to
target life-changing breakthroughs to help
people better manage Type 1 diabetes
and ultimately find cures for the disease.
An insulin-pramlintide co-formulation
will allow people with type 1 diabetes to
achieve better glucose control, improving
quality of life and in all likelihood ultimately
reducing long-term complications."
www.jdrf.org.uk
Nemaura's sugarBEAT CGM combined
with Changing Health's evidence based
digital health coaching solution to reduce
both HbA1c and weight loss.
The collaboration with Changing
Health is one of a number of initiatives
Nemaura has embarked upon as it seeks
to improve how people with diabetes
and prediabetes can manage, reverse
and prevent Type 2 diabetes through its
BEATdiabetes health subscription service
coupled with sugarBEAT CGM.
Professor Mike Trenell, Founder &
Chairman at Changing Health, said: "This
is an exciting collaboration, which we
believe will empower people with Type
2 diabetes with a real-time view of how
they're managing their condition. Doing
this each day is the best motivator there
can be, and we're looking forward to
working with Nemaura to create positive
behavioural change at scale."
See our Kit That's Coming Soon
article on p.26 for more info on
sugarBEAT.
£1MILLIONI MORE FOR JDRF
On World Diabetes Day in November
2019 the Steve Morgan Foundation
made a further charitable pledge of £1m
to support Type 1 diabetes research.
Businessman and philanthropist
Steve Morgan, and his wife Sally, who is a
trustee of the Foundation, had their family
life impacted by Type 1 diabetes in 2017
when Sally's son, Hugo, was diagnosed
with the condition at the age of seven.
The Morgan family has committed to
making a difference and funding research
so that advances towards finding a cure
can be made.
The foundation had already pledged
£3m to JDRF's mission to cure the
condition. The additional £1m pledge came
as the Morgans attended the Sugarplum
Dinner in London. The pledge will help
fund JDRF's research programme, which
includes immunotherapy studies the aim
of which is to reset the immune system
response seen in T1D. The research
programme also includes 'smart' insulin
research, which could allow people with
T1D to have just one injection a week,
instead of several a day. The pledge
will also enable JDRF to accelerate vital
clinical trials and ensures research can be
boosted in an attempt to cure T1D, and to
enhance current technologies, helping to
make them available on the NHS.